J Cancer
2022; 13(12):3326-3332.
doi:10.7150/jca.76719 This issueCite
Research Paper
Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to De Novo Acute Lymphoblastic Leukaemia
Hye Won Kook1*, Jin Ju Kim2*, Mi Ri Park2, Ji Eun Jang1, Yoo Hong Min1, Seung-Tae Lee2, Saeam Shin2✉, June-Won Cheong1✉
1. Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. 2. Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. *These authors contributed equally to this work.
✉ Corresponding authors: June-Won Cheong, M.D. Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. Tel: +82-2-2228-1970; E-mail: JWCHEONG70ac; Saeam Shin, M.D. Department of Laboratory Medicine, Yonsei University College of Medicine, Severance Hospital, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. Tel: +82-2-2228-2436; E-mail: saeam0304ac.More
Citation:
Kook HW, Kim JJ, Park MR, Jang JE, Min YH, Lee ST, Shin S, Cheong JW. Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to De Novo Acute Lymphoblastic Leukaemia. J Cancer 2022; 13(12):3326-3332. doi:10.7150/jca.76719. https://www.jcancer.org/v13p3326.htm
Background: Unlike therapy-related myeloid neoplasms, therapy-related acute lymphoblastic leukaemia (tr-ALL) is poorly defined due to its rarity. However, increasing reports have demonstrated that tr-ALL is a distinct entity with adverse genetic features and clinical outcomes.
Methods: We compared the clinicopathological characteristics and outcomes of patients diagnosed with tr-ALL (n = 9) or de novo ALL (dn-ALL; n = 162) at a single institution from January 2012 to March 2021. The mutational landscapes of eight tr-ALL and 63 dn-ALL patients were compared from a comprehensive next-generation sequencing panel.
Results: All tr-ALL patients had the B-cell phenotype. The most frequently mutated genes were IKZF1 (37%), CDKN2A (14%), SETD2 (13%), and CDKN2B (11%) in dn-ALL, whereas TP53 (38%) and RB1 (25%) mutations were most common in tr-ALL. tr-ALL patients did not show a statistically significant difference in overall survival (p = 0.70) or progression-free survival (p = 0.94) compared to dn-ALL patients.
Conclusions: In this study, we determined the clinical and genetic profiles of Korean patients with tr-ALL. We found alterations in genes constituting the TP53/RB1 pathway are more frequent in tr-ALL. Due to the rarity of the disease, multi-institutional studies involving a larger number of patients are required in future study.
Keywords: next-generation sequencing, therapy-related acute lymphoblastic leukaemia, germline predisposition, de novo acute lymphoblastic leukaemia, mutation
Citation styles
APA
Kook, H.W., Kim, J.J., Park, M.R., Jang, J.E., Min, Y.H., Lee, S.T., Shin, S., Cheong, J.W. (2022). Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to De Novo Acute Lymphoblastic Leukaemia. Journal of Cancer, 13(12), 3326-3332. https://doi.org/10.7150/jca.76719.
ACS
Kook, H.W.; Kim, J.J.; Park, M.R.; Jang, J.E.; Min, Y.H.; Lee, S.T.; Shin, S.; Cheong, J.W. Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to De Novo Acute Lymphoblastic Leukaemia. J. Cancer 2022, 13 (12), 3326-3332. DOI: 10.7150/jca.76719.
NLM
Kook HW, Kim JJ, Park MR, Jang JE, Min YH, Lee ST, Shin S, Cheong JW. Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to De Novo Acute Lymphoblastic Leukaemia. J Cancer 2022; 13(12):3326-3332. doi:10.7150/jca.76719. https://www.jcancer.org/v13p3326.htm
CSE
Kook HW, Kim JJ, Park MR, Jang JE, Min YH, Lee ST, Shin S, Cheong JW. 2022. Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to De Novo Acute Lymphoblastic Leukaemia. J Cancer. 13(12):3326-3332.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.